Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT
The Journal of Clinical Endocrinology & Metabolism · 14.07.2023 · 108 (8) · 1981-1997
DOI: 10.1210/clinem/dgad058 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 03.02.2023. Verfasst von Kimball A Johnson und 11 weiteren Autor:innen. Beteiligte Einrichtung: iResearch Atlanta, LLC, Decatur, Georgia 30030, USA. Hauptthemen laut MEDLINE: Hot Flashes, Menopause. Die Arbeit wurde bisher 198-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Astellas Pharma Inc.
Abstract (Originalsprache)
Context
Vasomotor symptoms (VMS) are common, bothersome, and can persist for years before and after menopause.
Objective
We aimed to assess efficacy/safety of fezolinetant for treatment of moderate to severe VMS associated with menopause.
Methods
In this double-blind, placebo-controlled, 12-week phase 3 trial with a 40-week active treatment extension (NCT04003142; SKYLIGHT 2), women aged 40 to 65 years with minimum average 7 moderate to severe VMS/day were randomized to 12 weeks of once-daily placebo, fezolinetant 30 mg, or fezolinetant 45 mg. Completers were rerandomized to fezolinetant 30/45 mg for 40 additional weeks. Coprimary efficacy endpoints were mean daily change from baseline to week 4 (W4) and W12 in VMS frequency and severity. Safety was also assessed.
Results
Both fezolinetant doses statistically significantly reduced VMS frequency/severity at W4 and W12 vs placebo. For VMS frequency, W4 least squares mean (SE) reduction vs placebo: fezolinetant 30 mg, –1.82 (0.46; P < .001); 45 mg, –2.55 (0.46; P < .001); W12: 30 mg, –1.86 (0.55; P < .001); 45 mg, −2.53 (0.55; P < .001). For VMS severity, W4: 30 mg, −0.15 (0.06; P < .05); 45 mg, −0.29 (0.06; P < .001); W12: 30 mg, −0.16 (0.08; P < .05); 45 mg, −0.29 (0.08; P < .001). Improvement in VMS frequency and severity was observed by W1 and maintained through W52. Serious treatment-emergent adverse events were infrequent, reported by 2%, 1%, and 0% of those receiving fezolinetant 30 mg, fezolinetant 45 mg, and placebo, respectively.
Conclusion
Daily fezolinetant 30 and 45 mg were efficacious and well tolerated for treating moderate to severe VMS associated with menopause.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- iResearch Atlanta, LLC, Decatur, Georgia 30030, USA.
- Employee of Astellas Pharma Global Development at the Time of the Study, Northbrook, IL, USA.
- Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, and Research Center for Reproductive Medicine and Gynecological Endocrinology - Menopause Unit, Fondazione Policlinico IRCCS S. M…
- Department of Obstetrics and Gynecology, UNC School of Medicine, Chapel Hill, NC 27599, USA.
- Department of Family and Community Medicine, University of Toronto, Toronto, Ontario M5S 1A1, Canada.
- Department of Obstetrics and Gynecology, Inselspital, Bern CH-3010, Switzerland.
ORCID-Profile: Nanette Santoro
Förderung
- Astellas Pharma Inc
Zitieren
APA
Johnson, K. A., Martin, N., Nappi, R. E., Neal-Perry, G., Shapiro, M., Stute, P., Thurston, R. C., Wolfman, W., English, M., Franklin, C., Lee, M., & Santoro, N. (2023). Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT. The Journal of Clinical Endocrinology & Metabolism, 108(8), 1981-1997. https://doi.org/10.1210/clinem/dgad058
Vancouver
Johnson KA, Martin N, Nappi RE, Neal-Perry G, Shapiro M, Stute P, et al. Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT. The Journal of Clinical Endocrinology & Metabolism. 2023;108(8):1981-1997. doi:10.1210/clinem/dgad058
BibTeX
@article{Johnson2023,
author = {Johnson, Kimball A and Martin, Nancy and Nappi, Rossella E and Neal-Perry, Genevieve and Shapiro, Marla and Stute, Petra and Thurston, Rebecca C and Wolfman, Wendy and English, Marci and Franklin, Catherine and Lee, Misun and Santoro, Nanette},
title = {Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
volume = {108},
number = {8},
pages = {1981--1997},
doi = {10.1210/clinem/dgad058}
}
EUVIMED